Answer questions and earn CME/CNE Cancer and heart disease are the leading causes of
morbidity and mortality in the industrialized world. Modern treatment strategies have led to …

Novel targeted cancer therapies, especially kinase inhibitors, have revolutionized the
treatment of many cancers and have dramatically improved the survival of several types of …

The humanized monoclonal antibody bevacizumab (Avastin®) has been available in the EU
since 2005. Results of phase III trials demonstrate that adding intravenous bevacizumab to …

Addition of anti-VEGF antibody therapy to standard chemotherapies has improved survival
and is an accepted standard of care for advanced non–small cell lung cancer (NSCLC) …

Recognition and management of treatment-related cardiovascular toxicity, defined as either
an acute cardiac event or a chronic condition, has been tightly integrated into routine cancer …

Neo-angiogenesis is a critical process for tumor growth and invasion and has become a
promising target in cancer therapy. This manuscript reviews three currently relevant anti …

Aim Apatinib, an oral tyrosine kinase inhibitor mainly targeting VEGFR‐2, exerts both
antiangiogenesis and antiproliferation effects. Apatinib shows clinical benefit in advanced …

In human patients, drugs that block tumor vessel growth are widely used to treat a variety of
cancer types. Many rigorous phase 3 clinical trials have demonstrated significant survival …

Introduction Arterial hypertension and proteinuria are common side effects of antiangiogenic
treatment and might represent a biomarker of response in patients with glioblastoma. The …

G-protein coupled receptors (GPCRs) constitute the largest family of membrane receptors,
with high potential for drug discovery. These receptors can be activated by a panel of …